Bliss GVS Pharma (506197) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024.

• Board reviewed agenda for issuance of Sweat Equity Shares, with further steps to be considered in the future.

Financial highlights

• Standalone revenue from operations for the quarter ended December 31, 2024: ₹17,959.37 lakh; total income: ₹19,125.43 lakh.

• Standalone net profit for the quarter: ₹2,072.00 lakh; for nine months: ₹5,751.66 lakh.

• Consolidated revenue from operations for the quarter: ₹21,041.82 lakh; total income: ₹22,568.33 lakh.

• Consolidated net profit for the quarter: ₹2,580.34 lakh; for nine months: ₹7,360.27 lakh.

• Earnings per share (EPS) for the quarter: Standalone ₹2.00 (basic), Consolidated ₹2.27 (basic).

Outlook and guidance

• Board and auditors confirm compliance with Indian Accounting Standards and regulatory requirements.